© 2024 © 2020 Genprex Inc. All Rights Reserved.
Technology for modulating autoimmunity expands intellectual property portfolio
Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer
Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes